Real-world utilization of aromatase inhibitors, tamoxifen, and ovarian function suppression in premenopausal patients with early hormone receptor-positive, HER2-negative breast cancer with increased recurrence risk - Müller, Volkmar; Hörner, Manuel; Thill, Marc; Banys-Paluchowski, Maggie; Schmatloch, Sabine; Fasching, Peter Andreas; Harbeck, Nadia; Langanke, Dagmar; Uhrig, Sabrina; Häberle, Lothar; Fischer, Dorothea; Hein, Alexander; et al. (The breast, 2025)
Online verfügbar: 22. März 2025, Artikelversion: 26. März 2025